Crossmark

Brentuximab vedotin containing salvage followed by consolidation post autologous hematopoietic stem cell transplantation in high risk relapsed refractory classical Hodgkin lymphoma

Crossref DOI link: https://doi.org/10.1038/s41409-020-0935-0

Published Online: 2020-05-13

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Damlaj, Moussab https://orcid.org/0000-0001-8326-2193
Abuelgasim, Khadega A.

Alhejazi, Ayman

Alahmari, Bader https://orcid.org/0000-0002-6026-1347
Alaskar, Ahmed https://orcid.org/0000-0002-0648-3256
Alzahrani, Mohsen
License Information

Text and Data Mining valid from 2020-05-13

Version of Record valid from 2020-05-13
More Information

Article History

Received: 16 March 2020

Revised: 24 April 2020

Accepted: 28 April 2020

First Online: 13 May 2020

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below